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The three-dimensional conformation of a protein is an important property and plays a key role
in its biological activity. We show here that ion mobility-mass spectrometry (IM-MS) can be
used to detect conformational changes in the protein ubiquitin in the gas phase induced by
reaction with the anticancer drug cisplatin. The primary adduct was ubiquitin-{Pt(NH3)2}
under denaturing conditions. Up to three different conformations appear to be generated upon
platination depending on the charge state. The collision cross-sections () for each conforma-
tion indicate that the conformations of the platinated protein are contracted in size compared
with unmodified ubiquitin with generally smaller  values. Ion mobility-tandem MS allowed
determination of the platinum binding site without a requirement for prior chromatographic
separation. A rapid 30-min digestion of cisplatin-modified ubiquitin with trypsin allowed the
platination site to be identified as the N-terminal methionine following low-energy collision-
induced dissociation (CID) studies of the modified peptide. The data were generated using a
Traveling-Wave based ion mobility-MS approach. Such cisplatin-induced shape changes may
have a significant effect on its function in vivo. This work highlights the usefulness of
the ion-mobility mass spectrometry technique for shedding new light on such protein
interactions. (J Am Soc Mass Spectrom 2010, 21, 1097–1106) © 2010 Published by Elsevier Inc.
on behalf of American Society for Mass SpectrometryCisplatin, cis-[PtCl2(NH3)2], and other plati-num-containing drugs have become extremelysuccessful and widely used as anticancer
drugs in the clinic, particularly for the treatment of
ovarian, testicular, head, and neck cancers [1]. While
its interaction with DNA is considered to be the key
event for exerting its toxic effect in cancer cells [2, 3],
cisplatin can also readily interact with a number of
potential protein and peptide targets in the body. It
has been previously found that within 24 h, 65%–90%
of the administered platinum is bound to proteins in
blood plasma [4]; such platinum–protein interactions
reduce the level of excreted platinum and increase the
deposition of platinum in tissues [5]. Such reactions
may contribute to the toxic side-effects exhibited in
patients, especially nephrotoxicity and hearing loss
[6], but may also contribute the mechanism of cancer
cell toxicity.
Ion mobility-mass spectrometry (IM-MS) has been
used extensively to interrogate complex biomolecules
(e.g., DNA, proteins) in the gas phase [7–14], yielding
useful information concerning their conformation and
structure. This technique could also be applied to probe
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further understand their biological implications in vivo.
The small, highly conserved protein ubiquitin (UBQ,
average molecular weight 8564.9 Da) plays a crucial
role in ubiquitination pathways and has direct and
indirect roles in tumor propagation [15]; it is therefore a
potential drug target in cancer cells. Cisplatin has been
shown to have inhibitory effects on the ubiquitination
process of proteins in vitro [16] and it is therefore of
relevance to investigate not only the platinum binding
site(s) on ubiquitin but also any induced conforma-
tional changes.
There are many reports of studies of reactions of
platinum complexes with proteins, including cyto-
chrome c, human serum albumin (HSA), metallothio-
nein, and -globulin [17–21], using various techniques
such as flameless atomic absorption spectroscopy
(FAAS), UV-Vis spectroscopy, 1D 1H NMR, and 2D
inverse detection [1H,15N] HSQC NMR studies using
15N-enriched cisplatin. In particular, a number of re-
ports have focused on the reaction of cisplatin with
UBQ [22–25]. In one previous study, it was concluded
that the primary binding site for cisplatin on UBQ is the
N-terminal methionine residue [22]. Oxidation of Met1
significantly reduced its reactivity towards cisplatin but
it was not possible to isolate and characterize a plati-
nated peptide resulting from trypsin digestion of the
protein. Further support for Met1 as the primary bind-
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tandem FT-ICR-MS (top-down MS) approach [25],
which allowed detection of a platinated peptide ion of
sequence [1MQIF4  Pt  2H].
Here, we have investigated the binding of cisplatin
to UBQ using a traveling-wave-based ion mobility-
tandem mass spectrometry approach. We have investi-
gated induced conformational changes upon platina-
tion of intact UBQ, and characterized a platinated
peptide product ion following intact tandem MS and a
rapid 30-min digestion using trypsin [26]. The location
of the platinated amino acid residue was determined by
direct analysis of trypsin digested cisplatin-modified
UBQ using low-energy collision induced dissociation
(CID).
Experimental
Materials
Ubiquitin from bovine red blood cells was purchased
from Fluka (Dorset, UK) and used without further
purification. Cisplatin (CDDP) was synthesized accord-
ing to literature methods [27]. Acetonitrile (HPLC
grade) and water (HPLC grade) were purchased from
Fisher Scientific (Loughborough, UK). Formic acid and
trypsin were purchased from Sigma Aldrich (T 1426;
Sigma-Aldrich Corp., St Louis, MO, USA), and ammo-
nium acetate was purchased from Fluka.
Reaction Between UBQ and Cisplatin
Aqueous solutions of UBQ (1 mg/mL) and the plati-
num complex cisplatin (1 mM) were prepared and
mixed to give a protein:platinum complex molar ratio
of 1:10. The samples were incubated at 37 °C for 24 h,
and then centrifuged either using pre-washed Centri-
con YM-3 filters (MW cut off  3 kDa (Millipore,
Watford, UK)) at 7000 RPM for 2 h at 4 °C, or Amicon
Ultra filters (MW cut off  3 kDa (Millipore, Watford,
UK)) at 7500 RPM for 1 h at 4 °C, to remove unbound
platinum, and washed twice with 1 mL water. Samples
were then diluted as appropriate to a concentration of
10 M, before MS analysis.
Tryptic Digestion Protocol
In summary, a 100 L aliquot of the stock solution
[either 100 M UBQ or 100 M UBQ  Cisplatin (1:10)]
was denatured by adding 20 L 50% aqueous acetoni-
trile with 0.5% formic acid (vol/vol). A 6 L aliquot of
ammonium bicarbonate (1 M) and 5 L trypsin (5
mg/mL) were then added, and the resulting solution
incubated for 30 min at 37 °C. The solution was then
diluted tenfold with 5:4 acetonitrile:water with 0.2%
formic acid before MS analysis.Ion Mobility-Mass Spectrometry
ESI-MS was performed on a Traveling-Wave based ion
mobility-mass spectrometer, the Synapt (High Defini-
tion Mass Spectrometer) HDMS (Waters Corporation,
Manchester, UK) [28]. The ion mobility section com-
prises three consecutive, gas filled, traveling wave
(T-Wave) rf ion guides. Ions are accumulated in the first
(Trap) T-Wave and periodically released into the sec-
ond (Mobility cell) T-Wave, where they separate ac-
cording to their mobility through action of a continuous
train of transient DC voltage pulses (traveling waves).
The separated ions are then propelled through the third
(Transfer) T-Wave into the oa-TOF analyzer for mass
analysis.
The instrument was operated with a capillary volt-
age of 3.0 kV. The ion source block and nitrogen
desolvation gas temperature were set to 80 and 100 °C,
respectively. The Trap and Transfer T-Wave sections
were operated at 2.3  102 mbar of sulphur
hexafluoride (SF6), and the ion mobility T-Wave at 3.0
mbar of helium. The Mobility T-Wave was operated
with a velocity of 250 m/s and the pulse height opti-
mized between 7 and 9 V. The HDMS spectra were
obtained in ‘V’ mode operating with 10,000 full width
half maximum (FWHM). All mass spectra were ac-
quired in positive-ion mode. Data acquisition and pro-
cessing were carried out using MassLynx (Waters Cor-
poration, Manchester, UK) (ver. 4.1) software supplied
with the instrument. The systematic approach taken
here, as with previous studies which have been com-
prehensively discussed [29–37], was to calibrate the
T-Wave ion mobility device with species of known
collision cross-section () determined using standard
drift tube instruments [38]. Where single charged 
values are reported, the mobility T-Wave was calibrated
with ions formed from a tryptic digest of human
hemoglobin. Multiply charged ions of sperm whale
myoglobin and ubiquitin with known  values were
used to calibrate the mobility T-Wave where  values
for multiply charged ions of cisplatin-modified UBQ are
reported.
Results
A typical mass spectrum of a 10 M (50% aqueous acetoni-
trile containing 0.1% formic acid) cisplatin-modified UBQ
solution obtained using direct infusion (4 L/min) is
shown in Figure 1a. Charge states were detected for
both unmodified and cisplatin-modified UBQ ranging
from 9 to 5 over the m/z acquisition range shown.
The base peak in the mass spectrum is that of unmod-
ified UBQ, [UBQ  7H]7. The peak cluster at m/z
1256.8 (see inset) indicates the most abundant platinum-
containing adduct of UBQ, i.e., [UBQ  {Pt(NH3)2}
5H]7 detected under the specified experimental condi-
tions, along with other mono-, bi- and tri-functional
adducts with UBQ, i.e., {Pt(NH3)}, {Pt(NH3)2(H2O)}, and
{Pt(NH3)2Cl}. Figure 1b shows the typical Maximum
ts fo
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nated UBQ. The spectrum contains both mono-adducts
(labeled a–d) and also less abundant bisadducts
(labeled e– h). The mono-adducts were observed at
mass 8775.2, 8792.0, 8810.1, and 8828.4 and are assig-
ned as {Pt(NH3)}, {Pt(NH3)2}, {Pt(NH3)2(H2O)}, and
{Pt(NH3)2Cl} adducts, respectively. The bisadducts (la-
beled e–h) observed at mass 9002.1, 9019.5, 9037.2, and
9055.5 are ascribed to adducts with {Pt(NH3) 
Pt(NH3)2}, {Pt(NH3)2 Pt(NH3)2}, {Pt(NH3)2 Pt(NH3)2
(H2O)}, and {Pt(NH3)2(H2O)2}2 or {Pt(NH3)2Cl 
Pt(NH3)2}, respectively. All of these observed adducts
are consistent with previous data obtained for the same
system [22, 24].
Figure 2 shows an overlay of the observed arrival
time distributions (ATDs, or ion mobility drift times) for
unmodified UBQ (black line), with the bi- and mono-
dentate cisplatin-modified UBQ adducts {UBQ 
Pt(NH3)2} (red line) and {UBQ  Pt(NH3)} (blue line)
under denaturing conditions for the charge states 9
(a), 8 (b) and 7 (c), respectively. Referring first to
unmodified UBQ, some of the ATDs showed evidence
of multiple conformational states. For example, al-
though [UBQ  9H]9 appears to have a single confor-
mation, with a single Gaussian peak shape observed in
Figure 1. The ESI mass spectrum of denatured
the maximum entropy deconvoluted ESI mass s
a–d) and bisadducts (labeled e–h) (b) Masses ar
highlighting the different platinum mono-adducthe ATD centered around 4.54 ms, both [UBQ  8H]8and [UBQ 7H]7 possess more than one conformation
(black outline in Figure 2) as is evident by the ATD.
Similar observations have previously been reported [38]
for the latter two multiply charged ions of unmodified
UBQ.
Upon platination, the composite nature of the ATDs
of the platinated UBQ species implies that multiple
conformations are produced for all charge states. The
majority of both platinated species forms were observed
to have higher mobilities compared with their unmod-
ified UBQ counterparts with the same charge state,
implying a contraction in size. From the measured ion
mobility drift times of each multiply charged ion de-
tected, the individual rotationally-averaged T-wave 
values for the unmodified and platinated UBQ species
were then calculated, and are shown in Table 1 (with
helium used as the mobility gas). The published litera-
ture  values for UBQ are shown for comparison [12,
39]. To further aid comparison, a plot of the measured
values versus charge state is shown in Figure 2d. The 
values of both the cisplatin-modified UBQ adducts also
illustrate a reduction in size of between 2% and 5%
compared with unmodified UBQ, confirming an overall
increase in compactness of the UBQ structure upon
platination. This trend is clearly shown for the larger
following reaction with cisplatin (1:10) (a) and
um containing platinum mono-adducts (labeled
erimental. The inset shows the 9 charge state,
rmed.UBQ
pectr
e expconformers generated for both platinated adducts,
3 2
d lite
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pending on the charge state, on comparison of the
smallest conformer  values generated for the [UBQ 
{Pt(NH3)2}] and [UBQ  {Pt(NH3)}] species (e.g., com-
parison of   1519.724 and 1389.061 Å2, respectively,
in the 9 charge state), a further reduction in the 
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Figure 2. Comparative ATDs of [UBQ 7H]7,
5H]7 (a); [UBQ  8H]8, [UBQ  {Pt(NH3)} 
9H]9, [UBQ  {Pt(NH3)}  7H]
9, and [UBQ
unmodified UBQ (—), the blue line [UBQ  {Pt(N
Comparison of experimentally derived T-Wave
(n 2)H]n (blue diamonds) and [UBQ {Pt(NH
specified experimental conditions, with publishe
Table 1. T-wave experimentally derived  [or collision cross
section values (CCS)] values for cisplatin-modified UBQ adducts
of [UBQ  {Pt(NH3)2}  (n  2)H]
 and [UBQ  {Pt(NH3)} 
(n  2)H] under denaturing conditions at various charge
states, with published UBQ  values
Charge
(n)
Calculated Cross Section (CCS, Å2)
[UBQ]a
[UBQ  {Pt(NH3)2} 
(n  2)H](n)
[UBQ  {Pt(NH3)} 
(n  2)H](n)
9 1519.724 1389.061
9 1649 1645.988 1645.996
9 1819.914 1829.906
8 1442 1407.936 1361.852
8 1622 1608.027 1608.034
7 1231.000 1158.783
7 1317 1340.676 1340.683
7 1580 1481.745 1481.752aReferences [12, 39].value of up to 9% accompanies the apparent loss of a
single ammonia group. It is of interest that this trend is
observed for the smallest conformer only and not for
the other generated conformers.
A detailed investigation was then performed to locate
the platinum binding site. MS-based methods have been
previously used in attempts to characterize the exact
binding site of cisplatin on UBQ using FT-ICR-MS, follow-
ing an intact tandem MS (top-down) approach [25]. A
product ion was detected at m/z 713.2 (based on 195Pt)
following tandem MS of the ion at m/z 1096.1 [UBQ 
{Pt(NH3)}
2  6H]8. Through the use of accurate mass
measurement, this ion was characterized as [MQIF 
{Pt}  2H], with MQIF (Met-Gln-Ile-Phe) being the first
four amino acid residues of the N-terminus of UBQ. The
location of the platinated amino acid could not be deter-
mined through the intact tandem MS approach.
The reported FT-ICR-MS experiments [25] were ini-
tially repeated by performing intact tandem MS on the
cisplatin-modified UBQ ion [UBQ  {Pt(NH3)2}
2 
6H]8 (m/z 1099.1) (see Figure 3). As previously ob-
served, upon top-down fragmentation the expected
diagnostic platinated-b4 adduct product ion was de-
tected at m/z 713.2 ([Pt  H2N-
1MQIF4  2H]). Tan-
CC
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(NH3)2}  7H]
9 (c). The black line represents
}] (—), and the red line [UBQ  {Pt(NH3)2}] (—).
lues for the conformers of [UBQ  {Pt(NH3)} 
 (n 2)H]n (red triangles) obtained under the
rature values for UBQ (black squares [12, 39] (d).0
[UBQ
6H]8
 {Pt
H3)
 va
) }dem MS of the precursor ion detected at m/z 1071.6 for
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Figure 3 shows the accurate mass spectrum for the three
most intense isotopes in the cluster. The mass resolution
afforded by the oa-TOF provided an accurate assign-
ment of an elemental formula for each of the isotopic
peaks around m/z 713.2 (Table 2). The accurate mass
measurements are consistent with previous data ob-
tained on the FT-ICR-MS instrument and confirm the
identity of the ion as the b4 (C25H38N5O5S) adduct with
{Pt}2, i.e., [(C25H38N5O5S)  {Pt}
2  2H]. No ions
containing Pt were detected below m/z 712.2. In addi-
tion to the MS information, the ATDs of the b4 ion
and platinated-b4 adduct product ion were measured
using T-wave ion mobility, and their individual ro-
Figure 3. Partial diagnostic tandem MS spe
cisplatin-modified UBQ (precursor ion m/z 1100)
diagnostic platinated ion of m/z 713.2.
Table 2. Accurate mass and elemental formula for the
platinated fragmented N-terminal b4 ion (
1MQIF4  {Pt}2 
2H]) and platinated a1 methionine immonium ion (
1M 
{Pt}2NH3]

Measured
mass
Theoretical
mass
Deviation
(ppm) Generated formula
712.2072 712.2064 1.1 C25H36N5O5
194Pt
713.2095 713.2085 1.4 C25H36N5O5
195Pt
714.2116 714.2087 4.1 C25H36N5O5
196Pt
313.0284 313.0270 4.5 C4H11N2S
194Pt
314.0279 314.0291 3.8 C4H11N2S
195Pt
196315.0284 315.0292 2.5 C4H11N2S Pttationally-averaged  values were determined. The
platinated-b4 adduct product ion has a very similar
drift time to the b4 product ion (3.33 and 3.39 ms,
respectively) with calculated  values of 158.4 Å2 and
158.6 Å2, respectively.
At this point, the platination site had still not been
unequivocally identified, and consequently a rapid 30-
min tryptic digest protocol was used on solutions of
both UBQ and cisplatin-modified UBQ. Figure 4 shows
the partial mass spectra obtained from the tryptic
digests of UBQ (a) and cisplatin-modified UBQ (b). The
presence of ions m/z 210/2 higher than the [UBQT1 
2H]2 ion (1MQIFVK6, Met-Gln-Ile-Phe-Val-Lys, m/z
383.2, T1 refers to tryptic peptide 1) in (b) shows, as
expected, that platination occurs in this peptide. It
should be noted that peak annotation, excluding the
diagnostic ions of m/z 383.2 and 488.7 has been removed
for clarity. The inset in Figure 4 shows an expanded
view of the doubly-charged isotopic cluster detected at
m/z 488.7, corresponding to [UBQT1  {Pt(NH3} 
2H]2. The doubly-charged ions [UBQT1  2H]2 (Fig-
ure 5a) and [UBQT1  {Pt(NH3)}  2H]
2 (Figure 5b)
were then further sequenced by tandem MS using
low-energy CID to determine the platinum binding site.
Following CID of the selected platinated precursor ion,
C-terminal product ions were detected for y1-y4 to-
obtained following mobility separation of
inset shows the accurate mass obtained for thectrum
. Thegether with {y5-NH3}, with the expected y5 ion not
isot
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were detected for b3-b5
, with the platinated b2
 ion not
being detected. Both spectra show immonium ions for
methionine and phenylalanine at m/z 104.1 and 120.1.
Upon fragmentation, the intensity of the methionine
immonium ion is reduced following binding of
{Pt(NH3)}
2. The reverse is found for the phenylalanine
immonium ion. A product ion peak was detected at m/z
314.0 in (b) but was absent in (a) following tandem MS
of the selected precursor ions. This peak is assigned as
a platinum adduct of the immonium ion of methionine,
methionine-{Pt(NH3)}. The mass increase of 210 Da
observed between the two spectra places the platinum
modification on position 1, the N-terminal methionine
of the modified peptide. The inset shown in Figure 5
shows the accurate mass spectrum for the platinated ion
detected at m/z 314.0. The accurate mass measured for
the immonium ion of methionine detected at m/z 104.0
was 104.0526. The software-generated elemental for-
mula of C4H10NS, showed a deviation of 7.7 ppm
from the theoretical mass of 104.0534. The elemental
composition determined for the peaks in the isotope
cluster detected around m/z 314 is also shown in Table
2. These data therefore provide evidence that platina-
Figure 4. The partial mass spectra of the 30-min
UBQ. The presence of ions m/z 210/2 higher
refers to tryptic peptide 1) in (b) shows that pla
shows an expanded view of the doubly-chargedtion occurs on the N-terminal methionine residue, andrepresent the first direct observation of this by mass
spectrometry-based techniques.
In addition to the MS information, the ion mobility
drift times of UBQ [UBQT1 2H]2 and modified UBQ
[UBQT1  {Pt(NH3)}  2H]
2 peptide ions were mea-
sured using T-wave ion mobility, and their individual
rotationally-averaged  values were determined. The
modified [UBQT1 {Pt(NH3)} 2H]
2 peptide ion had
a faster drift time compared with the [UBQT1  2H]2
ion suggesting a more compact structure, with  values
calculated as 211.4 Å2 and 213.4 Å2, respectively. It is of
interest to note that, as previously observed for the
platinated b4 ion, a measurable structural distortion can
be quantified (although the platinating species is
slightly different structurally, i.e., {Pt(NH3)}
2).
Discussion
Cisplatin and other platinum-based drugs are known to
have a strong binding preference for sulfur sites in
proteins, especially the thioether sulfur of methionine
and the thiolate of cysteine. However, although methi-
onine S is often the kinetically-preferred site (fastest to
react), bonds to N in the imidazole ring of histidine are
tic digest of (a) UBQ and (b) cisplatin-modified
the [UBQT1  2H]2 (MQIFVK, m/z 383.2, T1
ion occurs in this peptide. The inset in Figure 4
opic cluster detected around m/z 488.7.tryp
than
tinatoften stronger and thermodynamically favored. In this
s mea
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possible binding to Met1 and His68, which are the only
Met and His residues present in UBQ [40]. UBQ does
not contain any cysteine residues.
Under the denaturing conditions used and by anal-
ysis of short tryptic fragments, Met1 has been identified
in this study as the primary binding site. This result
agrees with previous conclusions based on indirect
methods [22, 25]. The generation of mono [UBQ  {Pt}]
adducts can be rationalized on the basis of known
platinum(II) chemistry. First, displacement of a chloride
leaving group on cisplatin by methionine S is likely to
be the first step in the reaction. There are several
possibilities for the second step. Aquation of the Pt-Cl
bond could give a reactive Pt-OH2 complex, which
might be followed by chelate ring formation and dis-
placement of the second Cl ligand on PtII by the amino
terminal nitrogen, giving a six-membered ring, Such
chelate formation occurs readily for methionine itself on
reaction with cisplatin and related complexes [41, 42].
Another possible second step is liberation of a NH3
ligand due to the large trans effect of the thioether sulfur
(weakening of the bond trans to Pt-S in the square-
planar complex) [43, 44]. This is more likely to occur
under acidic conditions when the liberated NH3 would
Figure 5. Tandem MS spectra obtained from
(MQIFVK, m/z 383.2) and (b) the cisplatin-modifi
487.7). The 210 Da mass-increase between (a) and
platination site. The inset shows the accurate masbe readily protonated. Although the initial reactionswere carried out at close to neutral pH, formic acid was
added during the trypsin digestion step and again to
the aqueous acetonitrile solution used for MS analysis.
These possible reaction pathways are depicted in Figure
6. Similar pathways have also been discussed by Gibson
and Costello [22]. In model systems, it is common for
adducts of cisplatin to contain S-bound methionine as
the kinetically favored product, but the sulfur can then
be displaced by nitrogen from, e.g., the imidazole ring
of histidine when there is a competing His residue
present. UBQ does contain a His residue, but no trans-
fer from Met1 to His68 was observed under the condi-
tions used (37 °C, 24 h).
Although such platination of UBQ (with Pt plus
ligands) would be expected to increase the size of the
protein and give rise to an increase in its collision cross
section, induced structural changes might result in the
observed decrease in effective size; for example, chela-
tion of Met1 would restrict the free movement of the
flexible N-terminus (as in species b or j in Figure 6).
Gibson and Costello found under initial native condi-
tions that unfolding (or denaturation) of the protein
could occur as a consequence of platination, particu-
larly with mono-dentate platinated species [22]; how-
ever, in contrast, under the denaturing conditions used
he unmodified [UBQT1  2H]2 peptide ion
Q [UBQT1 Pt(NH3) 2H]
2 peptide ion (m/z
upon the methionine immonium ion identifies the
surement of the platinated species of m/z 314.(a) t
ed UB
(b)in this work, the majority of adducts have smaller
itin (
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(particularly for the 9 charge state) in the smallest
conformer of the mono- and bi-dentate adducts may
provide evidence for the so-called “intramolecular link”
discussed by Gibson and Costello [22]. Such a link
could be formed through interaction with a secondary
site on the protein, e.g., through the nearby Glu16 or
Glu18 residues (based on crystal structure data [45]).
The presence of Pt-NH3, Pt-OH2, or Pt-Cl groups in the
product provides H-bond donors or acceptor (Cl) that
can interact with distant H-bond acceptors (e.g., CO)
or donors (e.g., NH, OH) (species akin to structure a= in
Figure 6). Also, upon formation of the Pt-Met chelate,
the promoted loss of one of the ammonia ligands could
allow formation of a formal bond between platinum
and the free carboxylate group of the Glu16/Glu18 side
chains (species akin to structure a in Figure 6). A
further possibility that was considered was that upon
chelation at the Met site, the promoted loss of one of the
ammonia ligands could allow for an interaction of a
deprotonated amide NH site along the peptide back-
bone. Platinum-induced deprotonation of backbone
amide NH sites has been proposed to occur in peptides
and proteins e.g., in the product after reaction of
cisplatin with the protein transferrin [46], but tends to
occur in X-Met sequences where 6-membered rings can
be formed and not at isolated amide NH sites.
Small structural changes to UBQ may have biological
relevance, interfering for example in the second or third
UBQ polymeric attachment required for the ubiquitina-
tion tagging process, leading to down-regulation of
protein ubiquitination and destruction. Isoe et al. have
reported that cisplatin can inhibit both ubiquitin-ATP-
dependent proteolysis and the ubiquitination of pro-
teins through interaction with the enzyme(s) involved
Figure 6. Potential reaction pathways for th
observed in the reaction of cisplatin with ubiquin UBQ conjugation, via studies using fraction II fromrabbit reticulocyte lysates (which contains ubiquitin-
ATP-dependent protease, E1, E2, and E3 enzymes), but
with no apparent interaction with UBQ itself [16]. This
result was unexpected, considering the body of litera-
ture mentioned in this work on their direct interaction,
but the use of a relatively short incubation time in the
latter study (1 h) could account for this observation.
The effect of platination on small peptides produced
from direct fragmentation in the MS instrument has
also been investigated, with platination of the top-down
fragmented 4aa b4 peptide ion (
1MQIF4 with {Pt2})
leading to a small but reproducible reduction in the 
value, suggesting a more compacted structure. This is of
interest since the overall molecular weight of the plati-
nated peptide has increased by 37%. A similar trend
was also found for the platinated 6aa peptide ion after
tryptic digest (1MQIFVK6, UBQT1) with a similar coor-
dinated Pt species ({Pt(NH3)}
2), where a small reduc-
tion in the  value was also observed with an increase
in the molecular weight of 27%.
Conclusions
T-Wave ion mobility-MS instrumentation was used for
determining the binding site of the anticancer drug
cisplatin on the protein UBQ, and also to investigate
protein shape changes induced by platination. Through
this MS study, direct evidence has been obtained to
show that platinum is bound to the N-terminal methi-
onine residue. Under the specified experimental condi-
tions and through the use of electrospray ionization, the
[UBQ  {Pt(NH3)2}] mono-adduct was found to be the
most abundant species following a 24 h reaction between
cisplatin and UBQ (1:10, molar ratio). Ion mobility-intact
tandem MS offers the advantage that overlapping ionic
rmation of platinated mono-adduct products
also refer to reference [22] for further details).e fospecies can be mobility-resolved before generating the
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tryptic digestion protocol for determining the location of
platinum in the platinum-containing fragments. The di-
gestion protocol is highly reproducible with MS evidence
directly indicating that the platinated moiety remains
attached to the UBQ following digestion. This approach
does not require any prior chromatographic separation.
Furthermore, we have calculated  values and de-
termined the effect of platinum binding upon the mo-
bility of UBQ, the b4 product ion (
1MQIF4) following
intact tandem MS, and also the tryptic peptide T1
(1MQIFVK6). Our results indicate that although a sub-
stantial amount of mass was added through binding of
the platinum fragment, the modified structures are
more compact in comparison to their unmodified coun-
terparts. These results highlight the fact that small
structural distortions upon platination can be measured
and quantified in the gas phase using ion mobility on a
rapid milli-second timescale. The cross section of the
intact protein also appears to contract slightly upon
platination, although the number of conformations gen-
erated is dependent on the charge state and the attached
platinum fragment. Such a shape change may have a
significant effect on its function in vivo. Although the
distribution of species present in the gas-phase of MS
experiments may be different from that present in
solution, it is likely the cross sections of the adducts are
similar. This work highlights the usefulness of ion-
mobility mass spectrometry for shedding new light on
such protein interactions.
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